trending Market Intelligence /marketintelligence/en/news-insights/trending/In4JyfZTc7vrgYl4uwXbCw2 content esgSubNav
Log in to other products

 /


Looking for more?

Contact Us
In This List

Biogen completes spinoff of hemophilia unit

Blog

Global M&A Infographic Q1 2021

Blog

Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Blog

COVID-19 Impact & Recovery: Private Equity

COVID-19 Impact & Recovery: Corporates


Biogen completes spinoff of hemophilia unit

Biogen Inc. completed the spinoff of its global hemophilia unit.

The new company, Bioverativ, is an independent publicly traded global biotechnology company specializing in hemophilia and other rare blood disorders, Biogen said in a news release.

Bioverativ common stock will begin regular way trading Feb. 2 on the Nasdaq Global Select Market under the symbol BIVV.

Biogen was advised by Goldman Sachs & Co. and Guggenheim Securities LLC.